Literature DB >> 21944797

Retroperitoneal lymph node dissection for metastatic germ cell tumours.

N Haldipur1, S Devaraj, A Shehata, A K Lewis, M O Smith, M Hatton, A Nassef, J D Beard.   

Abstract

INTRODUCTION: In the North Trent Cancer network (NTCN) patients requiring retroperitoneal lymphadenectomy for metastatic testicular cancer have been treated by vascular service since 1990. This paper reviews our experience and considers the case for involvement of vascular surgeons in the management of these tumours. PATIENTS AND METHODS: Patients referred by the NTCN to the vascular service for retroperitoneal lymphadenectomy between 1990 and 2009 were identified through a germ cell database. Data were supplemented by a review of case notes to record histology, intraoperative and postoperative details.
RESULTS: A total of 64 patients were referred to the vascular service for retroperitoneal lymph node dissection, with a median age of 29 years (16-63 years) and a median follow-up of 4.9 years. Ten patients died: eight from tumour recurrence, one from septicaemia during chemotherapy and one by suicide. Of the 54 who survived, 7 were alive with residual masses and 47 patients were disease-free at the last follow-up. Sixteen patients required vascular procedures: four had aortic repair (fascia), three had aortic replacement (spiral graft), four had inferior vena cava resection, two had iliac artery replacement and two had iliac vein resection.
CONCLUSIONS: Retroperitoneal lymph node dissection often involves mobilisation and/or the resection/replacement of major vessels. We recommend that a vascular surgeon should be a part of testicular germ cell multidisciplinary team.

Entities:  

Mesh:

Year:  2011        PMID: 21944797      PMCID: PMC3363081          DOI: 10.1308/003588411X571098

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  33 in total

Review 1.  Regular review: Managing testicular cancer.

Authors:  D Dearnaley; R Huddart; A Horwich
Journal:  BMJ       Date:  2001-06-30

Review 2.  Laparoscopic RPLND for clinical stage I nonseminomatous germ cell testicular cancer: current status.

Authors:  Sam B Bhayani; Mohamad E Allaf; Louis R Kavoussi
Journal:  Urol Oncol       Date:  2004 Mar-Apr       Impact factor: 3.498

3.  Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.

Authors:  Axel Heidenreich; Peter Albers; Michael Hartmann; Sabine Kliesch; Kai-Uwe Kohrmann; Susanne Krege; Philipp Lossin; Lothar Weissbach
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

Review 4.  Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy.

Authors:  J Baniel; A Sella
Journal:  Semin Surg Oncol       Date:  1999-12

5.  The hazards of anesthesia and surgery in bleomycin-treated patients.

Authors:  P L Goldiner; O Schweizer
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

6.  Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses.

Authors:  William F Hendry; Andrew R Norman; David P Dearnaley; Cyril Fisher; Judy Nicholls; Robert A Huddart; Alan Horwich
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

Review 7.  Part II: testicular cancer--management of advanced disease.

Authors:  Robert H Jones; Paul A Vasey
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

8.  Laparoscopic retroperitoneal lymph node dissection after chemotherapy.

Authors:  Michael A Palese; Li-Ming Su; Louis R Kavoussi
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

Review 9.  Epidemiology of testicular cancer.

Authors:  Rustom P Manecksha; John M Fitzpatrick
Journal:  BJU Int       Date:  2009-11       Impact factor: 5.588

10.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses.

Authors:  Jan Oldenburg; G Cecilie Alfsen; Hans H Lien; Nina Aass; Håkon Waehre; Sophie D Fossa
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.